New paper puts FOXL2 back in focus for canine XX DSD
Bottom line
A new paper in Sexual Development argues that FOXL2 should move higher on the candidate-gene list for canine 78,XX disorder/difference of sex development (DSD) in SRY-negative dogs, especially in French Bulldogs. The article, by Paulina Krzeminska, is a review and hypothesis-driven analysis rather than a report of a newly confirmed causal mutation. It notes that canine XX DSD has long been studied through the lens of SOX9, and more recently PADI6, but says FOXL2 has been comparatively underexplored despite its central role in ovarian development and maintenance. The paper also points to increasing reports of XX DSD in French Bulldogs and suggests cryptic relatedness among affected dogs may indicate a shared genetic background. (karger.com)
Why it matters: For veterinary professionals, this doesn’t change diagnosis overnight, but it does sharpen the research and breeding conversation. Dogs with XX DSD can present with ambiguous external genitalia, testicular or ovotesticular tissue, infertility, and breed-line implications, and the molecular cause still isn’t fully resolved in many cases. Earlier work did not find an association between the specific FOXL2 polymorphisms studied in 2015 and canine XX DSD, which makes this new paper’s argument more about biologic plausibility and where to look next than about a settled answer. That matters for clinicians counseling pet parents, pathologists interpreting gonadal findings, and breeders or breed clubs considering how future genetic testing might evolve. (pubmed.ncbi.nlm.nih.gov)
What to watch: Watch for follow-up sequencing studies, particularly in French Bulldogs, that test FOXL2 more comprehensively, including hard-to-sequence GC-rich regions, and clarify whether it adds to or interacts with known SOX9- and PADI6-linked risk. (karger.com)
Key facts
- Study type
- Review and hypothesis-driven analysis
- Journal
- Sexual Development
- Topic
- Canine 78,XX disorder/difference of sex development in SRY-negative dogs
- Gene highlighted
- FOXL2
- Breed of focus
- French Bulldogs
- What the paper says
- FOXL2 should move higher on the candidate-gene list
- Prior finding
- A 2015 study found no association between studied FOXL2 polymorphisms and canine XX DSD
- Other genes mentioned
- SOX9 and PADI6
- Suggested next step
- Comprehensive FOXL2 sequencing, including GC-rich coding regions
A newly published paper in Sexual Development is putting FOXL2 back into the spotlight in canine XX disorder/difference of sex development (DSD). In SRY-negative 78,XX dogs, where chromosomal females develop testicular or ovotesticular tissue, author Paulina Krzeminska argues that FOXL2 is a biologically credible candidate gene that deserves deeper investigation, particularly in French Bulldogs. Importantly, the paper does not report a newly proven mutation. Instead, it reframes the field around a gene that may have been overshadowed by years of focus on SOX9. (karger.com)
That shift matters because canine XX DSD has been a stubborn genetics problem for years. Earlier work established that affected dogs lack the SRY gene, ruling out a simple Y-chromosome translocation explanation, and research groups have since pursued several candidate regions and mechanisms. A Cornell overview of the canine model describes this condition as a rare but valuable naturally occurring model for XX DSD, noting that affected XX littermates may develop testes or ovotestes and that the trait has been studied as an autosomal recessive pattern in a research pedigree. (pmc.ncbi.nlm.nih.gov)
The field has produced leads, but not a single universal answer. A 2015 study examined polymorphisms in CTNNB1 and FOXL2 and found no association between the variants it identified and canine XX testicular or ovotesticular DSD. Subsequent work kept attention on other loci, including SOX9-region copy number changes, and a 2022 genomics paper identified a PADI6 missense polymorphism associated with XX DSD in two breeds. Taken together, those findings suggest genetic heterogeneity, which helps explain why no one marker has fully accounted for cases across breeds. (pubmed.ncbi.nlm.nih.gov)
Krzeminska’s paper makes the case that FOXL2 still deserves another look. In the abstract, the author emphasizes FOXL2’s established role in ovarian differentiation and maintenance, along with functional evidence from mouse models. The paper also highlights that 78,XX DSD has been increasingly reported in French Bulldogs, a breed already burdened by other inherited health concerns, and says observed cryptic relatedness among affected dogs may point to a shared genetic background. The recommendation is practical: future work should include comprehensive sequencing of FOXL2, especially GC-rich coding regions, paired with careful clinical phenotyping. (karger.com)
Industry reaction is still limited, which isn’t surprising for an early, hypothesis-forward paper in a niche clinical-research area. But the broader literature supports the paper’s logic. Reviews of DSD biology describe FOXL2 as a key ovarian pathway regulator, and veterinary and comparative-genomics groups have repeatedly framed canine XX DSD as a useful model for understanding how ovarian pathways fail to suppress testis development in the absence of SRY. That doesn’t validate FOXL2 as the cause in dogs, but it does support the paper’s central argument that the gene is mechanistically relevant enough to warrant another, more technically thorough pass. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinarians, the immediate clinical takeaway is modest, but real. This paper doesn’t create a new diagnostic test or alter case management today. What it does do is reinforce that ambiguous genitalia, infertility, or discordant gonadal findings in dogs, especially French Bulldogs, may sit within a more complex and breed-linked genetic landscape than a single-marker explanation can capture. That has implications for referral decisions, histopathology workups, genetic counseling, and conversations with pet parents about prognosis, breeding, and the limits of currently available testing. (pubmed.ncbi.nlm.nih.gov)
It also matters for population health. If FOXL2 or FOXL2-adjacent mechanisms are confirmed in future studies, breed clubs and diagnostic labs may eventually gain a more precise way to identify risk in lines where DSD appears to cluster. Until then, the safest interpretation is that the paper is a research signal, not a practice-changing breakthrough. (karger.com)
What to watch: The next step is clear: larger, breed-specific sequencing studies, likely focused on French Bulldogs, that test FOXL2 alongside established candidates such as SOX9-region variants and PADI6, and pair genotype data with standardized phenotyping to determine whether FOXL2 is causal, contributory, or simply adjacent to the real driver. (karger.com)